Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.6 USD | +8.11% |
|
+20.60% | +197.21% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 4.56 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+197.21% | 1.03B | B- | ||
+16.45% | 123B | B+ | ||
+21.96% | 115B | B+ | ||
+23.73% | 25.85B | B | ||
-20.05% | 20.9B | B+ | ||
-16.28% | 16.77B | B | ||
-16.52% | 16.52B | A- | ||
-44.35% | 15.56B | A- | ||
+63.91% | 15.49B | C+ | ||
+2.52% | 13.45B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ARQT Stock
- Ratings Arcutis Biotherapeutics, Inc.